Why the study?
Does tranexamic acid reduce composite bleeding outcomes in patients undergoing noncardiac surgery?
Does tranexamic acid reduce composite bleeding outcomes in patients undergoing noncardiac surgery?
In patients undergoing noncardiac surgery, tranexamic acid reduces bleeding but its cardiovascular safety (noninferiority) compared to placebo was not definitively established.
Answers are grounded in this paper and cite their sources.
Reduces bleeding in noncardiac surgery; cardiovascular noninferiority not established, leaving safety unresolved for further trials.
Among patients undergoing noncardiac surgery, the incidence of the composite bleeding outcome was significantly lower with tranexamic acid than with placebo. Although the between-group difference in the composite cardiovascular outcome was small, the noninferiority of tranexamic acid was not established. (Funded by the Canadian Institutes of Health Research and others; POISE-3 ClinicalTrials.gov number, NCT03505723.).
No takes yet. Share an insight, caveat, or question.
Devereaux et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: